Until two years ago, only two classes of smoking cessation drugs were available: nicotine replacement therapy (NRT) with multiple delivery methods (gum, patch, inhaler, spray, lozenge) and the mild antidepressant bupropion. All approximately double the rate of cessation when compared to placebo. Chantix (Varenicline) is the first new agent for smoking cessation approved in almost a decade and represents a third class of drug with a different mechanism of action than either nicotine replacement...
